Study Feasibility Outcomes
After excluding viral loads before mid-October 2020 which may have been affected by the defective analyzer, we retrospectively identified 262 nonpregnant adults with a true VL ≥1000 copies/mL who were receiving first-line ART between mid-October 2020 and March 2022 and may have been eligible for enrolment. During the same period, we were able to screen 65 and enroll 62 of 262 participants (23.7%), approximately 3.6 per month. The other 18 enrolments (to make the total of 80) occurred before mid-October 2020 and were known to not have been affected by the laboratory error. Overall, 76 of 80 participants (95.0%, 95% CI: 87.0 to 98.4) attended the study exit visit; 38 of 39 (97.4%, 95% CI: 84.9 to 99.9) in the intervention arm and 38 of 41 (92%, 95% CI: 79.0 to 98.1) in the standard-of-care arm. Two participants relocated, and 2 were lost to follow-up and not contactable.